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Abstract
Objectives: To evaluate the performance of the American College of Rheumatology (ACR)/European League Against
Rheumatism (EULAR) 2010 classification criteria for rheumatoid arthritis (RA) with a systematic literature review and a meta-
analysis.
Methods: PubMed, Embase, Cochrane Library and the abstracts of the ACR and EULAR meetings (2010–2012) were searched
for original articles or abstracts with the following inclusion criteria: 1) recent onset arthritis, with at least one swollen joint
and no alternative diagnosis; 2) the ACR/EULAR 2010 criteria as index test; 3) the prescription of methotrexate (MTX) or
disease modifying antirheumatic drugs (DMARDs) at any time during follow-up as reference standard. Data were pooled
using the bivariate model. Three meta-analyses were performed with MTX (primary analysis), DMARDs or their combination
(secondary analyses) as reference standard. Heterogeneity was formally tested and explored performing an influence
analysis.
Results: The search identified 1,277 references. Six full papers and 4 abstracts met the inclusion criteria. With MTX as
reference standard, sensitivity (95% confidence interval, CI) was 0.80 (0.74,0.85), specificity 0.61 (0.56,0.67), positive
likelihood ratio (LR) 2.11 (1.92,2.32), negative LR 0.31 (0.25,0.38) and the diagnostic odds ratio (DOR) was 6.74 (5.49,8.28).
Using DMARDs as reference standard, sensitivity was 0.73 (0.64,0.80), specificity was 0.74 (0.68,0.79), LR+2.85 (2.53,3.22), LR2
0.35 (0.27,0.45) and DOR 8.03 (6.4,10.09). Using the combination of MTX and DMARDs as reference standard, intermediate
results were obtained. The influence analysis detected one potentially influential study. However, its exclusion from the
meta-analysis did not have a clinically relevant impact on the results.
Conclusions: The new classification criteria have good sensitivity, lower specificity and an overall moderate diagnostic
accuracy. These results confirm that the criteria have classificative and not diagnostic function.
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Introduction
In the last few decades, the recognition of the central role of an
early diagnosis and the early administration of disease modifying
antirheumatic drugs (DMARDs), particularly methotrexate
(MTX), greatly improved the management of rheumatoid arthritis
(RA) [1]. The more effective diagnostic and treatment strategies
led to a better control of the disease with a deeper suppression of
synovitis [2] and the prevention of radiological progression of bone
erosions in the joints [3]. All these improvements have led to a
great reduction of the risk of permanent disability [4,5] which is
the most significant long-term detrimental consequence of the
disease.
For these reasons, the early recognition of RA has become a
central issue in clinical practice, although the absence of a single
and reliable test to identify the disease does not always allow an
immediate diagnosis. The American College of Rheumatology
(ACR) proposed in 1987 a set of classification criteria, developed
in patients with longstanding disease with the aim to be specific
rather than sensitive [6]. These criteria, that were initially meant
for the enrolment of patients in clinical trials, but in some cases are
used for diagnosis, have shown an unsatisfactory performance in
the setting of early arthritis, especially due to a low sensitivity [7].
The inadequate performance of the 1987 criteria led in recent
years to the development of prognostic algorithms, meant to
discriminate, at the time of symptom onset, patients with higher
probability of persistent disease amenable to treatment with
DMARDs from those with self-limiting arthritis [8,9].
In 2010 the ACR and the European League Against
Rheumatism (EULAR) jointly developed new classification crite-
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ria, aiming to allow earlier patient classification, treatment and
inclusion in clinical trials [10]. The new criteria were developed
from inceptional cohorts of inflammatory arthritis data [11] which
subsequently integrated with expert opinion [12] and finally
validated in external early arthritis cohorts. For their development,
the reference standard for diagnosis was the prescription of MTX
or other DMARDs within the first year of observation. This was
considered the best available reference standard, reflecting the risk
of chronicity and erosive damage [10]. Since the criteria were
developed using a reference standard that can be fulfilled after a
follow-up, their value is not only classificative, but also prognostic.
The opinion of an expert rheumatologist was not considered an
acceptable reference standard because the widespread knowledge
of the 1987 classification criteria would have likely lead to a
circularity bias.
The 2010 criteria include tender and swollen joint count, acute
phase reactants, anti-cyclic citrullinated peptide antibodies (ACPA)
or rheumatoid factor (RF), and symptom duration (Table 1).
These clinical and laboratory data are combined into a score
ranging from 0 to 10. In the validation cohorts, the areas under the
Receiving Operator Characteristics (ROC) curve (AUC) for the
new criteria ranged from 0.66 to 0.82, and the score that
determined an optimal discrimination was between 6 and 7. The
cut-off of 6 was afterwards chosen in order to improve sensitivity.
However, detailed information on the sensitivity and specificity of
the new criteria, along with the corresponding likelihood ratios
(LR), has not been reported in the original paper. Moreover, there
was a certain variability in accuracy measures across different
cohorts [13].
After their first presentation at the ACR congress in 2009, the
new criteria have been tested in a number of external early
arthritis cohorts with a wide variability in the overall performance
[14–17]. These studies are slightly different in terms of population,
but the main differences are in the assessment of the reference
standard. In fact, many studies considered expert opinion as
reference standard [15], as well as disease persistency, appearance
of bone erosions or the 1987 classification criteria [17]. Only some
of the studies considered the prescription of MTX or other
DMARDs as reference standard for diagnosis as indicated in the
newly developed criteria.
Because of the increasing knowledge on the 2010 RA classifi-
cation criteria it seemed timely to summarise the results of the
available literature. The present study aims to evaluate the
performance of the 2010 ACR/EULAR classification criteria in
populations of individuals with early arthritis. For this purpose, we
performed a systematic literature review and subsequent meta-
analyses in which we considered the 2010 classification criteria a s
index test, the prescription of MTX or other DMARDs as
reference standard for the classification of RA as done during the
development of the criteria.
Methods
The Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines for the reporting of systematic
reviews and meta-analysis were followed to conduct this review
[18]. A pre-specified protocol, including research question, search
strategy, inclusion criteria for the articles and methods for the
analysis, was developed before the beginning of the study.
Data Sources and Search
The search was performed by one of the authors (GS) and a
control search by a second author (CAS). We searched Medline
(PubMed), Embase and Cochrane databases from November 2009
(when the criteria were presented for the first time) to May 2012.
The search strategies are shown in table 2. The search strategy was
based on terms related to RA, classification and diagnosis. The
references of the included studies were manually screened to
search for further papers. The abstracts of the ACR (2010 and
2011) and EULAR congresses (2010, 2011, 2012) were examined
to look for additional studies. No language or publication
restrictions were applied and studies were not selected based on
quality. Filters developed for the identification of diagnostic studies
were not utilised since such filters may result in omission of
relevant studies [19].
Study Selection
Studies should include subjects presenting with recent onset
arthritis, with at least one swollen joint and no definite diagnosis
that could explain symptoms (that is, the same population in which
classification criteria should be applied) [10]. Finally, only data on
patients with RA or undifferentiated polyarthritis (UPA) at
baseline were included. The 2010 classification criteria were the
index test, in the score format; the presence of bone erosions was
not included since it was not tested in the data-driven phase of the
development. Moreover, a definition of typical erosions had not
yet been presented during the timespan that we examined. The
prescription of MTX or DMARDs was considered as reference
standard. In particular, we included studies that considered MTX
(alone) as reference standard or overall DMARDs (including also
MTX). Corticosteroids were not included.
Diagnostic cohort studies (prospective and retrospective) and
case control studies were eligible for inclusion in the review. The
presence of sufficient data to build a 262 table of diagnostic
performance was required. Two reviewers independently screened
titles and abstracts. The full-text of the potentially eligible articles
was obtained; inclusion assessment was performed by one reviewer
Table 1. 2010 ACR/EULAR classification criteria for
rheumatoid arthritis.
A Joint involvement
1 large joint 0
2–10 large joints 1
1–3 small joints 2
4–10 small joints 3
.10 joints 5
B Serology
Negative RF and negative ACPA 0
Low-positive RF or low-positive ACPA 2
High-positive RF or high-positive ACPA 3
C Acute-phase reactants
Normal CRP and normal ESR 0
Abnormal CRP or Abnormal ESR 1
D Duration of symptoms
,6 weeks 0
$6 weeks 1
The criteria are meant to be applied in patients with at least one swollen joint,
after the exclusion of other causes of synovitis. Patients with a score $6 are
classified as having RA. Also subjects with typical bone erosions can be
classified as RA regardless of the score. Modified from Aletaha D, et al. RF:
rheumatoid factor; ACPA: anti-cyclic citrullinated peptide antibodies; CRP: C-
reactive protein; ESR: erythrocyte sedimentation rate.
doi:10.1371/journal.pone.0056528.t001
Accuracy of Criteria for Rheumatoid Arthritis
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and checked by a second. Disagreements were resolved by
consensus. Only the most recent and complete report was
included in the case of studies reported in multiple publications
or abstracts.
Data Extraction and Quality Assessment
We extracted data using a standardised form. Results were
extracted as 262 tables. Studies were assessed for methodological
quality by using the modified version of the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) tool proposed by the
Cochrane Collaboration [20]. Data extraction and quality
assessment were done by one reviewer and checked by a second
reviewer.
Data Synthesis and Analysis
Sensitivity and specificity were calculated for each 262 set of
data. Heterogeneity among n included studies was visually
evaluated plotting sensitivity and specificity on a ROC graph,
and separately tested by the Chi-square test using n21 degree of
freedom [21].
In the presence of heterogeneity and negative correlation
between sensitivity and specificity, as commonly seen in diagnostic
studies, the bivariate model was used to estimate summary
sensitivity and specificity with 95% confidence intervals (CI) and to
derive a hierarchical summary receiving operator characteristic
(HSROC) curve [22–24].Summary positive and negative likeli-
hood ratios (LR+, LR2) and the diagnostic odds ratio (DOR) were
derived for each analysis.
Three different analyses were performed. Primary analysis used
MTX as reference standard for diagnosis. Secondary analysis used
DMARDs as reference standard for diagnosis. Since MTX is a
particular type of DMARDs, and in order to increase the number
of available studies and hence the precision of the meta-analysis, a
third analysis used MTX or DMARDs as reference standard was
performed. For this analysis, if data on both MTX and DMARDs
were reported separately, data on DMARDs were used.
To evaluate the robustness of our findings, we performed an
influence analysis calculating Cook’s distance for each study. This
index is a measure of the influence of a study on the model
parameters and can be used to check for particularly influential
study. Studies with Cook’s distance $1 were considered poten-
tially influent. A further meta-analysis was then performed after
excluding these potentially influential studies.
Publication bias was indirectly evaluating the symmetry on the
funnel plot of logDOR. Forest plots were used to represent
sensitivity and specificity of the primary studies.
Finally to verify the presence of publication bias, a funnel plot
was implemented.
Review Manager (RevMan) version 5 (The Nordic Cochrane
Centre, The Cochrane Collaboration, Copenhagen) was used to
build the forest plot showing sensitivity and specificity of single
studies and the risk of bias tables. Stata, version 11, (StataCorp,
College Station, Texas) was used to perform all analyses. In
particular the generalized linear mixed model approach to
bivariate meta-analysis of sensitivity and specificity was obtained
using the ‘metandi’ command of Stata.
Results
The search strategy identified 1277 studies. Figure 1 reports the
flow-chart of the process of study selection. 6 articles were included
after the evaluation of all titles and abstracts [14,16,25–28].
Moreover, 4 abstracts from the ACR and EULAR congresses
were eligible for inclusion [29–32]. In total, 4 papers used MTX as
unique reference standard, 3 used DMARDs as unique reference
standard, while 3 studies reported separate data on both MTX
and DMARDs. Two studies [15,33] were excluded since they used
a composite reference standard based on concomitant expert
opinion and DMARDs and expert opinion was not considered an
acceptable reference standard for this review. Table 3 and Figure 2
summarise the main features of the included studies. Figure 2
shows the point estimates with 95% CIs of sensitivity and
specificity for the included studies. Sensitivity ranged from 0.68
to 0.88 when MTX was considered as reference standard, and
from 0.59 to 0.87 when DMARDs were used. The specificity
ranged from 0.50 to 0.72 with MTX as reference standard, and
from 0.64 to 0.88 with DMARDs.
The evaluation of the methodological quality of the included
studies is shown in Figure 3. All studies had a low risk of bias for
most of the items except for blinding that was not explicitly
mentioned in any of the studies. For this reason, the blinding of the
results of the reference standard and the index test was considered
unclear. All the included studies had an overall low risk of bias; for
this reason, additional analyses, excluding those for low-quality
studies, were not performed, since the results of the meta-analysis
would not be affected by a low methodological quality.
Both sensitivity and specificity showed significant heterogeneity,
with a Chi-square for differences across studies of 29.01
(p,0.0001) and 17.09 (p = 0.009) respectively.
Table 4 summarises the results of all the meta-analyses. Using
MTX as reference standard, pooled sensitivity (95% CI) was 0.80
(0.74, 0.85) and pooled specificity (95% CI) was 0.61 (0.56, 0.67), a
LR+ of 2.11 (1.92, 2.32) and a LR2 of 0.31 (0.25, 0.38).
Table 2. Search strategy.
PubMed 1 ‘‘rheumatoid arthritis’’
2 Arthritis, rheumatoid[Mesh]
3 #1 OR #2
4 ‘‘classification’’
5 ‘‘diagnostic criteria’’
6 ‘‘ACR EULAR’’
7 #4 OR #5 OR #6
8 #3 AND #7
Embase 1 ‘rheumatoid arthritis’/exp AND [embase]/lim
2 ‘classification criteria’ AND [embase]/lim
3 acr AND eular
4 #2 OR #3
5 #1 AND #4 AND [embase]/lim AND [1-6-2009]/sd AND
[2009–2012]/py
Cochrane #1 MeSH descriptor Arthritis, Rheumatoid, this term only
#2 rheumatoid arthritis
#3 (#1 OR #2)
#4 classification
#5 diagnostic criteria
#6 ACR EULAR
#7 (#4 OR #5 OR #6)
#8 (#3 AND #7)
Limits: humans, adults, from November 2009.
doi:10.1371/journal.pone.0056528.t002
Accuracy of Criteria for Rheumatoid Arthritis
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Using DMARDs as reference standard, sensitivity was 0.73
(0.64,0.80), specificity was 0.74 (0.68,0.79), LR+ was 2.85
(2.53,3.22) and LR2 was 0.35 (0.27,0.45).
The third analysis, combining MTX and DMARDs, led to
intermediate results (Figure 4).
The influence analysis using the Cook’s distance identified Van
Der Linden’s study as a potentially influential [27]. After removing
this study the pooled sensitivity changed from 0.80 (0.74, 0.85) to
0.79 (0.72, 0.84), and specificity from 0.61 (0.56, 0.67) to 0.60
(0.53, 0.68). The influence of each single study is reported in
Figure 5.
Funnel plot did not show any systematic asymmetry suggesting
the absence of publication bias (Figure 6).
Discussion
Since the new classification criteria for RA were first presented,
several studies have provided a wide range of results by evaluating
their performance in the setting of early arthritis. These studies
were different in terms of population (mainly due to the
recruitment criteria and calendar year into the existing cohorts)
and reference standard. Moreover, treatment patterns differed
significantly among them. This variability did not allow the
drawing of consistent conclusions from a single study. Therefore it
seemed appropriate to review the available literature on this topic.
We adopted a search strategy meant to be sensitive rather than
specific; the limited time period under exam allowed this
approach. We did not use pre-specified filters for diagnostic
accuracy studies [19]. Since the search was designed to be as broad
as possible, it is unlikely that relevant studies were missed. Even in
this way, the number of studies that were eligible for the inclusion
was limited. This is the main limitation of this review, since it did
not allow to investigate the causes of heterogeneity in detail and,
for the same reason, subgroup analyses were not feasible.
The majority of the validation studies did not use the same
reference standard highlighted in the development of the criteria
and many of them used expert opinion or the 1987 ACR criteria.
In particular, 13 studies that were selected for detailed review have
afterwards been excluded because of a wrong reference standard.
These studies were excluded because of the possibility of the
introduction of considerable circularity bias. Same reference
standard used to develop the new criteria were adopted, that is
the prescription of MTX or other DMARDs [10]. The results
obtained showed an overall moderate performance of the criteria
with acceptable values of sensitivity through all reference
standards. One the other hand, specificity was lower in the
analyses based on MTX, and MTX with DMARDs. The analysis
based on overall DMARDs as reference standard showed a better
specificity of the 2010 classification criteria. In fact, MTX might
not have been given to all patients that would require it due to
contraindications or national differences in prescriptions. On the
other hand sensitivity does not increase accordingly because a
twofold higher increase of subjects treated with DMARDs not
fulfilling the 2010 criteria is observed.
The values of LR+ were around 2.5, far from the values of LR+
.10 that ideally identify a test having the power to detect the
disease. However, LR2 were around 0.3, which is closer to the
optimal values of LR2 ,0.1 [34]. This indicates the patients not
fulfilling the 2010 classification criteria have high probability of
not having RA (and will not develop it later, if we consider that the
criteria identify patients that might fulfil an outcome after a follow-
up), while patients fulfilling them will not certainly develop RA. In
contrast with this consideration, the DORs suggest a good
Figure 1. PRISMA flow-chart describing the selection process in the systematic literature review.
doi:10.1371/journal.pone.0056528.g001
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Figure 2. Sensitivity and specificity of the included studies. A)methotrexate as reference standard B) disease modifying antirheumatic drugs
as reference standard C) methotrexate+ disease modifying antirheumatic drugs as reference standard.
doi:10.1371/journal.pone.0056528.g002
Accuracy of Criteria for Rheumatoid Arthritis
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performance, though this is probably driven by low values of
LR2.
The need to perform differential diagnosis before the applica-
tion of the criteria might have determined the underestimation of
their accuracy even if the majority of studies excluded patients that
were afterwards diagnosed with disease other than RA or UPA.
Differential diagnosis is not always feasible in the early stages; this
might have increased the number of false positives resulting in the
reduction of specificity.
In the original presentation paper, detailed data on sensitivity,
specificity and performance were not reported. The values of the
areas under the ROC curve (AUC) reported in the validation
cohorts ranged from 0.66 to 0.82. The best performance was
achieved in the Norwegian cohort of early arthritis, while in the
remaining two the AUCs were ,0.7; this indicates a test with
Figure 3. Assessment of the risk of bias in the included studies. 3A) Methodological quality graph: authors’ judgment about each
methodological quality item presented as percentages across all included studies. 3B) Methodological quality summary: authors’ judgment about
each methodological quality item for each included study. +: low risk of bias; ?: unclear risk of bias; -: high risk of bias.
doi:10.1371/journal.pone.0056528.g003
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moderate performance [10]. The differences between the popu-
lations could be due to differences in recruitment and treatment.
In the external validation cohorts, only the proportion of patients
correctly classified was reported, while overall estimates of
accuracy were not presented. Since not all information on the
performance of the 2010 criteria is provided in the original paper,
results could not be directly compared our with data from the
inception of the criteria.
As expected, significant heterogeneity was found among
diagnostic studies. This finding did not permit the separate
combination of sensitivity and specificity. For this reason we
adopted a bivariate model that allows for the negative correlation
between sensitivity and specificity. Given the low number of
studies, investigating heterogeneity by stratified meta-analysis or
meta-regression was not feasible. For this reason we evaluated the
robustness of our results by performing an influence analysis [21].
However, though one study was demonstrated to be potentially
influential, a subsequent meta-analysis after the exclusion of the
influential study led to comparable results.
All the included studies had an overall good methodological
quality. The items dealing with blinding were not explicitly
addressed by the papers, therefore the risk of bias related to
these points was considered unclear for all studies. Despite this,
given to the retrospective design and the unavailability of the
criteria at the time of the clinical assessment and therapeutic
decision, this did not clearly biased the results. The last two
items (on the report of uninterpretable results and withdrawals),
even though not directly reported, were considered satisfactory,
since, as suggested by the Cochrane collaboration, they
probably had no influence on the results [20]. Since the
methodological quality of all the included studies was good, the
results of the meta-analysis have likely not been affected by the
methodological quality of the primary studies.
A meta-analysis on the diagnostic performance of the 1987
ACR classification criteria demonstrated an overall sensitivity and
specificity of 0.77 in the subgroup of patients with early arthritis
and a better performance among cases of established arthritis [7].
These results are not substantially different from those of our
meta-analyses: the new criteria, specifically designed for early
arthritis, do not perform better than the old ones in the same
setting. However, it has to be kept in mind that the 1987 criteria
were developed based on expert opinion while the 2010 criteria
Table 4. Results of meta-analyses.
Reference standard Studies (n) Sensitivity (95% CI) Specificity (95% CI) LR+(95% CI) LR– (95% CI) DOR (95% CI)
MTX 7 0.80 (0.74,0.85) 0.61 (0.56,0.67) 2.11 (1.92,2.32) 0.31 (0.25,0.38) 6.74 (5.49,8.28)
DMARDs 6 0.73 (0.64,0.80) 0.74 (0.68,0.79) 2.82 (2.53,3.22) 0.35 (0.27,0.45) 8.03 (6.40,10.09)
MTX+DMARDs 10 0.76 (0.71,0.81) 0.69 (0.61,0.75) 2.48 (2.08,2.95) 0.33 (0.29,0.38) 7.38 (6.33,8.62)
95% CI: 95% confidence interval; LR+: positive likelihood ratio; LR2: negative likelihood ratio; DOR: diagnostic odds ratio; MTX: methotrexate; DMARDs: disease
modifying antirheumatic drugs.
doi:10.1371/journal.pone.0056528.t004
Figure 4. Results of the meta-analyses. A) methotrexate as reference standard; 7 studies included, 3845 participants. B) disease modifying
antirheumatic drugs s as reference standard; 6 studies included, 3018 participants. C) methotrexate+disease modifying antirheumatic drugs as
reference standard; 10 studies included, 4134 participants. The black square indicates the point estimate of sensitivity and specificity for the meta-
analysis, the dotted line indicates the 95% confidence interval. The continuous line is the hierarchical summary receiving operator characteristics
curve. The dots represent the primary studies.
doi:10.1371/journal.pone.0056528.g004
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used a more practical reference standard, such as the use of
specific treatment regimes. Therefore, the 2010 criteria could be
more useful in a clinical setting because they classify patients based
on a relevant prognostic aspect of the disease with an impact on
clinical management. Nevertheless, the function of the criteria is
classification, and not diagnosis; based on current knowledge the
2010 criteria should not be used as a guide to start specific
treatments for RA.
The external validation studies in the meta-analysis on 1987
criteria had a cross-sectional case-control design that overestimates
the accuracy while the cohort study design (such as in the
development of the criteria) tends to underestimate accuracy [35],
and this might have influenced our results as well.
One of the merits of the 2010 classification criteria is the fact
that it is not necessary to reach six weeks of symptom duration to
classify a patient as having RA. Only one study [14] applied the
new criteria in a population of very early arthritis, but their
performance did not seem substantially different that in the
remaining early arthritis population.
Figure 5. Results of meta-analyses excluding single studies. Overall meta-analysis, based on the primary analysis using methotrexate as
reference standard, and meta-analysis excluding a single study are reported. The table and the legend refer to the study that has been excluded.
doi:10.1371/journal.pone.0056528.g005
Figure 6. Funnel plot. The distribution of the studies in the funnel plot does not suggest the presence of publication bias. In fact, studies are
distributed by each side of the plot, with moreover a lower number of studies with positive results. In the case of publication bias, the opposite
situation would have been expected.
doi:10.1371/journal.pone.0056528.g006
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The creation of an optimal tool for the classification of
rheumatic disease, with RA in particular, has always been
challenging. This is mainly due to the absence of gold standards
for diagnosis. The decision to prescribe either DMARDs or MTX
is dependent from expert opinion and reflects a judgement on the
severity of arthritis, for this reason their performance does not
seem to be superior to the old ones. However developing the
criteria avoiding to use expert opinion as reference standard gives
an opportunity to innovate clinical practice, and we could expect
that the presentation of the new classification criteria might
significantly modify the approach to RA. In fact, the results of the
present meta-analysis evaluate the 2010 criteria in the setting of
the current management of RA by rheumatologists, but the final
judgement on the criteria will probably be drawn after prospective
studies, evaluating their long-term impact on disease outcomes.
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